iBio, Inc.(IBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,909 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
IBIO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for iBio, Inc. (IBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBIO at 10.5/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), iBio, Inc. reports net income of $-10.6M, free cash flow of $-6.2M. Top institutional holders of IBIO by reported 13-F value include Affinity Asset Advisors, Cormorant Asset Management, SILVERARC CAPITAL MANAGEMENT, based on the most recent SEC filings. IBIO trades on the Nasdaq exchange and files with the SEC under CIK 1420720. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for iBio, Inc. directly from SEC EDGAR. iBio, Inc.'s 13F Pro composite quality score has ranged between 3 and 30 since 2022, currently 10.5 — a declining long-term trajectory across 11 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-10.6M
Free Cash Flow
Q2 2026
$-6.2M
ROIC
Q2 2026
-53.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-75.0% YoYNet Income
-79.8% YoYOperating Income
-88.9% YoYEPS (Diluted)
+81.7% YoYTotal Assets
+327.5% YoYOp. Cash Flow
-51.7% YoYFree Cash Flow
-55.3% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $100.0K -75.0% | $400.0K +77.8% | $225.0K | $0.00 -100.0% | $1.9M -20.5% | $2.4M |
| Net Income | $-33.0M -79.8% | $-18.4M +26.2% | $-24.9M +61.7% | $-65.0M -29.2% | $-50.3M -116.8% | $-23.2M |
| Operating Income | $-35.1M -88.9% | $-18.6M -11.8% | $-16.6M +43.3% | $-29.3M +1.2% | $-29.7M +4.5% | $-31.1M |
| EPS (Diluted) | $-0.32 +81.7% | $-1.75 +46.2% | $-3.25 +93.9% | $-53.09 -1737.2% | $-2.89 -4716.7% | $-0.06 |
| Total Assets | $99.1M +327.5% | $23.2M -19.3% | $28.7M -30.3% | $41.2M -58.5% | $99.4M -32.4% | $147.0M |
| Operating Cash Flow | $-23.2M -51.7% | $-15.3M +17.5% | $-18.6M +39.0% | $-30.4M +18.8% | $-37.5M -24.7% | $-30.1M |
| Free Cash Flow | $-23.8M -55.3% | $-15.3M +18.4% | $-18.8M +48.1% | $-36.2M +19.3% | $-44.8M -28.1% | $-35.0M |
Get alerted when IBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for iBio, Inc. including:
Top Institutional Holders of IBIO
Affinity Asset Advisors, LLC
$7.0M4,007,881 shCormorant Asset Management, LP
$6.2M3,570,000 shSILVERARC CAPITAL MANAGEMENT, LLC
$6.2M3,520,490 shVestal Point Capital, LP
$4.5M2,600,000 shVANGUARD CAPITAL MANAGEMENT LLC
$3.7M2,098,151 shFrazier Life Sciences Management, L.P.
$3.4M1,953,467 shEnsign Peak Advisors, Inc
$3.2M1,832,457 shWoodline Partners LP
$3.1M1,776,547 shMILLENNIUM MANAGEMENT LLC
$2.9M1,651,473 shCITADEL ADVISORS LLC
$2.4M1,384,029 sh
| Fund | Value | Shares |
|---|---|---|
| Affinity Asset Advisors, LLC | $7.0M | 4,007,881 |
| Cormorant Asset Management, LP | $6.2M | 3,570,000 |
| SILVERARC CAPITAL MANAGEMENT, LLC | $6.2M | 3,520,490 |
| Vestal Point Capital, LP | $4.5M | 2,600,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.7M | 2,098,151 |
| Frazier Life Sciences Management, L.P. | $3.4M | 1,953,467 |
| Ensign Peak Advisors, Inc | $3.2M | 1,832,457 |
| Woodline Partners LP | $3.1M | 1,776,547 |
| MILLENNIUM MANAGEMENT LLC | $2.9M | 1,651,473 |
| CITADEL ADVISORS LLC | $2.4M | 1,384,029 |
Companies Similar to IBIO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Firy Inc.
Celldex Therapeutics, Inc.
C4 Therapeutics, Inc.
CytomX Therapeutics, Inc.
Prelude Therapeutics Inc
SUTRO BIOPHARMA, INC.
Voyager Therapeutics, Inc.
Virgin Galactic Holdings, Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put IBIO on your watchlist
Track score changes the day iBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IBIO a good stock to buy?
13F Pro's AI-powered analysis of iBio, Inc. (IBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IBIO are available on the IBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IBIO is classified as a small company.
Which hedge funds own IBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of iBio, Inc.'s investment landscape.